The current investigation's goal is to create and assess a flucytosine microemulgel. Flucytosine enters the fungal cell by the cytosine permease; as a result, flucytosine is converted inside of fungal cells into 5-fluorouracil and inhibits fungal thymidylate synthase. Its bioavailability is low. In the realm of pharmaceutical sciences, microemulgel has now emerged as one of the most intriguing topical preparations. When used as a delivery mechanism, microemulgel has several advantages over straightforward conventional formulations, including simplicity of administration, increased residence duration at the application site, constant drug release with improved bioavailability, superior thermodynamic stability, and excellent transdermal permeability. Using carbopol 940 and isopropyl myristate as gelling agents, triethanolamine as the oil, methyl parabens and liquid paraben as preservatives and propyl glycol as an emulgent and penetration enhancer, the flucytosine microemulgel is created. Visual examinations were done on the generated microemulgel formulation for things like Spreadability, homogeneity, viscosity, pH, percent drug content, and in vitro diffusion tests. The development of microemulgel containing flucytosine will be more successful, according to the results, but clinical trials are necessary to fully understand their clinical usefulness.